11 unchanged sentences
Purchased Under
−Removed: January 1, 2022 - January 31, 2022 715 (1)
+Added: April 1, 2022 - April 30, 2022 28,809 (1)
— $1,393,714,917
−Removed: February 1, 2022 - February 28, 2022 6,653,483 (1)
+Added: May 1, 2022 - May 31, 2022 839 (1)
— $1,393,714,917
−Removed: March 1, 2022 - March 31, 2022 1,048,640 (1)
+Added: June 1, 2022 - June 30, 2022 989 (1)
— $1,393,714,917
1 unchanged sentence
— $1,393,714,917
−Removed: In addition to AbbVie shares repurchased on the open market under a publicly announced program, if any, these shares also included the shares purchased on the open market for the benefit of participants in the AbbVie Employee Stock Purchase Plan – 715 in January;
−Removed: 692 in February;
−Removed: and 640 in March.
+Added: In addition to AbbVie shares repurchased on the open market under a publicly announced program, if any, these shares also included the shares purchased on the open market for the benefit of participants in the AbbVie Employee Stock Purchase Plan – 28,809 in April;
+Added: and 989 in June.
These shares do not include the shares surrendered to AbbVie to satisfy minimum tax withholding obligations in connection with the vesting or exercise of stock-based awards.
2 unchanged sentences
Exhibit Description
−Removed: Form of AbbVie Inc.
−Removed: Performance-Vested Restricted Stock Unit Agreement*
−Removed: Form of AbbVie Inc.
−Removed: Performance Share Award Agreement*
−Removed: Form of AbbVie Inc.
−Removed: Non-Employee Director RSU Agreement (US) *
−Removed: Form of AbbVie Inc.
−Removed: Non-Qualified Stock Option Agreement *
−Removed: Form of AbbVie Inc.
−Removed: Retention RSU Agreement – Ratable Vesting*
−Removed: Form of AbbVie Inc.
−Removed: Retention RSU Agreement – Cliff Vesting with Dividend Equivalent Accrual *
+Added: AbbVie Non-Employee Directors’ Fee Plan, as amended and restated *
Certification of Chief Executive Officer Required by Rule 13a-14(a) (17 CFR 240.13a-14(a)).
5 unchanged sentences
101 The following financial statements and notes from the AbbVie Inc.
−Removed: Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, filed on May 6, 2022, formatted in iXBRL (Inline eXtensible Business Reporting Language):
+Added: Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, filed on August 4, 2022, formatted in iXBRL (Inline eXtensible Business Reporting Language):
(i) Condensed Consolidated Statements of Earnings;
10 unchanged sentences
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
−Removed: /s/ Robert A.
−Removed: Vice Chairman, Finance and Commercial Operations and
+Added: Senior Vice President,
Chief Financial Officer (Principal Financial Officer)
+Added: August 4, 2022
2022 Form 10-Q |
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.